Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Stenzl

Showing results (191-200 of 199) with videos related to

Pageof 20
Sort By:
You have reached the last page of results.This site can display upto 199 results.
Oncology Reports|December 7, 2002
Limitations of tissue microarrays in the evaluation of focal alterations of bcl-2 and p53 in whole mount derived prostate tissuesAxel S Merseburger, Markus A Kuczyk, Jurgen Serth, et al.
Cancer Microenvironment : Official Journal of the International Cancer Microenvironment Society|February 6, 2015
Erratum to: Biomodulatory Treatment of Patients with Castration-Resistant Prostate Cancer: A Phase II Study of Imatinib with Pioglitazone, Etoricoxib, Dexamethasone and Low-Dose TreosulfanM Vogelhuber, S Feyerabend, A Stenzl, et al.
Cancer Microenvironment : Official Journal of the International Cancer Microenvironment Society|December 16, 2014
Biomodulatory Treatment of Patients with Castration-Resistant Prostate Cancer: A Phase II Study of Imatinib with Pioglitazone, Etoricoxib, Dexamethasone and Low-Dose TreosulfanM Vogelhuber, S Feyerabend, A Stenzl, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 18, 2025
Open versus robotic-assisted partial nephrectomy in patients with intermediate/high-complexity kidney tumours: final results of the randomised, controlled, open-label, multicentre trial OpeRaM-O Grimm, J Bedke, J Nyarangi-Dix, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 14, 2015
Impact of perioperative chemotherapy on survival in patients with advanced primary urethral cancer: results of the international collaboration on primary urethral carcinomaG Gakis, T M Morgan, S Daneshmand, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 18, 2025
Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 studyJ N Graff, M Burotto, P C Fong, et al.
World Journal of Urology|February 21, 2020
Correction to: The natural course of pT2 prostate cancer with positive surgical margin: predicting biochemical recurrenceA Karl, A Buchner, C Tympner, et al.
World Journal of Urology|February 16, 2015
The natural course of pT2 prostate cancer with positive surgical margin: predicting biochemical recurrenceA Karl, A Buchner, C Tympner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 20, 2019
EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†A Horwich, M Babjuk, J Bellmunt, et al.
Pageof 20

Showing results (191-200 of 199) with videos related to

Sort By:
Pageof 20
You have reached the last page of results.This site can display upto 199 results.
Oncology Reports|December 7, 2002
Limitations of tissue microarrays in the evaluation of focal alterations of bcl-2 and p53 in whole mount derived prostate tissuesAxel S Merseburger, Markus A Kuczyk, Jurgen Serth, et al.
Cancer Microenvironment : Official Journal of the International Cancer Microenvironment Society|February 6, 2015
Erratum to: Biomodulatory Treatment of Patients with Castration-Resistant Prostate Cancer: A Phase II Study of Imatinib with Pioglitazone, Etoricoxib, Dexamethasone and Low-Dose TreosulfanM Vogelhuber, S Feyerabend, A Stenzl, et al.
Cancer Microenvironment : Official Journal of the International Cancer Microenvironment Society|December 16, 2014
Biomodulatory Treatment of Patients with Castration-Resistant Prostate Cancer: A Phase II Study of Imatinib with Pioglitazone, Etoricoxib, Dexamethasone and Low-Dose TreosulfanM Vogelhuber, S Feyerabend, A Stenzl, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 18, 2025
Open versus robotic-assisted partial nephrectomy in patients with intermediate/high-complexity kidney tumours: final results of the randomised, controlled, open-label, multicentre trial OpeRaM-O Grimm, J Bedke, J Nyarangi-Dix, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 14, 2015
Impact of perioperative chemotherapy on survival in patients with advanced primary urethral cancer: results of the international collaboration on primary urethral carcinomaG Gakis, T M Morgan, S Daneshmand, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 18, 2025
Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 studyJ N Graff, M Burotto, P C Fong, et al.
World Journal of Urology|February 21, 2020
Correction to: The natural course of pT2 prostate cancer with positive surgical margin: predicting biochemical recurrenceA Karl, A Buchner, C Tympner, et al.
World Journal of Urology|February 16, 2015
The natural course of pT2 prostate cancer with positive surgical margin: predicting biochemical recurrenceA Karl, A Buchner, C Tympner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 20, 2019
EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†A Horwich, M Babjuk, J Bellmunt, et al.
Pageof 20